Topas Therapeutics Gmbh is the new spin-off created by Evotec to focus on the development of nanoparticle-based therapeutics to treat immunological disorders using a unique proprietary approach to tolerance. The operation has a total value of EUR 14 million.
The new company aims to reach the multiple sclerosis clinical proof-of-concept (“POC”) stage by the end of 2017. Topas emerges from the neuro portfolio of Bionamics GmbH, an early stage therapeutics company using ground breaking nanoparticle technology and acquired by Evotec in March 2014.